esc
Genre: Entertainment
by: lifeguards
Tout ce que vous navez jamais vu des Faitarts... the best of du Week end, des rush du film...tout
Genre: Funny Videos
by: tirel
This video will help you on how to lock your RC Diffs.
Genre: How-to
by: Go_Big_Videos
For more info visit www.newsinfusion.comMADIT-CRT Trial Results Provide Clinical Evidence That Cardiac Resynchronization Therapy Significantly Slows Heart Failure Progression Natick, MA and Barcelona (September 1, 2009) — Boston Scientific Corporation (NYSE: BSX) today announced final results from the landmark MADIT-CRT trial, which were published by the New England Journal of Medicine and presented during a Hot Line session at the annual European Society of Cardiology (ESC) Congress in Barcelona. Arthur Moss, M.D., Professor of Medicine at the University of Rochester Medical Center and Principal Investigator of the trial, presented the MADIT-CRT data. The primary endpoint showed that Boston Scientifics cardiac resynchronization therapy defibrillators (CRT-Ds) were associated with a 34 percent relative reduction in the risk of all-cause mortality or first heart failure event in asymptomatic and mild (NYHA Class I and II1) heart failure patients, when compared to standard implantable cardioverter ...
Genre: News Videos
by: newsinfusion
Some cool german(or swedish?) guy lip-syncing to "Carola - Invincible" Which represented Sweden in ESC 2006. The guy's SOOOO happy just just can't be sad looking at him :)
by: Pir4t
copilacion que resulto despues de aber intentado aser deportes la verdad si fue doloroso pero son puros errores jaja
by: SUPERKALCETIN
Check out my modified electric RC plane Pitts S2A performing amazingly on a 6MPH Crosswind day. After my personal taste modification, (30A Esc, 4500 RMP Motor, 13.5 x 7 Prop and 11.1v 1800mAh Li Poly Battery) this plane has nothing but Power and performance to offer. Check it out
by: ShanMao
Today at the Embedded Systems Conference (ESC) Silicon Valley, TechInsights, the daily source of essential business and technical information for the electronics industrys decision makers, unveiled plans for its first-ever online gathering of users, experts and technology providers focused on multicore, titled EE Times Multicore Virtual Conference. This live gathering, scheduled for June 18th 11am EDT - 6pm EDT, will include live online conference sessions about todays most pressing multicore issues led by industry experts, and will also feature the most complete collection of interactive educational content ever assembled on the topic. To view Multimedia News Release, go to http://www.prnewswire.com/mnr/techinsights/37675/
by: comments
Boston Scientific Corporation (NYSE: BSX) today announced final results from the landmark MADIT-CRT trial, which were published by the New England Journal of Medicine and presented during a Hot Line session at the annual European Society of Cardiology (ESC) Congress in Barcelona.Arthur Moss, M.D., Professor of Medicine at the University of Rochester Medical Center and Principal Investigator of the trial, presented the MADIT-CRT data. The primary endpoint showed that Boston Scientifics cardiac resynchronization therapy defibrillators (CRT-Ds) were associated with a 34 percent relative reduction in the risk of all-cause mortality or first heart failure event in asymptomatic and mild (NYHA Class I and II1) heart failure patients, when compared to standard implantable cardioverter defibrillators (ICDs) (p=0.001).To view Multimedia News Release, go to http://www.prnewswire.com/mnr/bostonscientific/36500/
Prof. Peter Sleight Dept of Cardiovascular Medicine Oxford, UK, comments on the outcome of the TRANSCEND trial The results of the TRANSCEND® trial demonstrate that telmisartan 80mg reduces the risk of cardiovascular death, myocardial infarction/heart attack and stroke in high-risk cardiovascular patients by 13% compared with those patients already receiving best standard of care (p=0.048), referring to the same endpoint as that defined as the primary endpoint of the landmark HOPE trial published in 2000.1,2 Therapy with telmisartan was well tolerated and showed a trend towards a lower rate of discontinuation.1 The new data on 5,926 patients from 40 countries were presented today at the annual congress of the European Society of Cardiology (ESC) in Munich, Germany. TRANSCEND®* is the first landmark trial to test and prove the cardiovascular protective effects of an angiotensin II receptor blocker (ARB) – Boehringer Ingelheim's telmisartan – versus placebo, on top of standard therapy (including ...
